Drug Profile
Research programme: inflammatory bowel disease therapeutics - Tillotts Pharma
Alternative Names: 5-ASA-based technology; Mesalamine-based technologyLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PLx Pharma
- Developer Tillotts Pharma
- Class
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammatory-bowel-disease in Switzerland
- 05 Jul 2011 Early research in Inflammatory bowel disease in Switzerland (unspecified route)